The intravenously delivered HER2-retargeted onco-immunotherapeutic HSV, named R-337, was found to be effective in inhibiting the growth of lung tumors, generated upon the IV administration of tumor cells, considered a model of metastatic disease [22]. The gene discussed is ERBB2; the disease is metastatic neoplasm.